Welcome back to Healthy Kidney Inc! Today, we are discussing a topic that is extremely important to anyone who wants to protect their new kidney and help it last as long as possible. If you are exploring an SGLT2 inhibitor kidney transplant treatment, you are in the right place. We are diving into an exciting new research video from late 2023 that could change how we approach post-transplant care.
SGLT2 inhibitor kidney transplant: Breakthroughs from 2023 Kidney Week
Recently, an eye-opening piece of research was presented at the 2023 ASN Kidney Week. The study provided a real-world analysis of sodium-glucose cotransporter-2 inhibitors in kidney transplant recipients. While this class of medications has been available for about a decade and is known to be highly beneficial for general kidney disease, the latest findings on these medications are truly groundbreaking.
Historically, major trials for these drugs excluded transplant patients. However, this new observational study—the largest of its kind to date—confirms what smaller reports have suggested. Utilizing an SGLT2 inhibitor kidney transplant protocol can significantly help a transplanted kidney last longer by reducing the risk of failure and rejection.
The Benefits: Beyond Just the Kidney
The most well-known medication in this class is Farxiga (dapagliflozin), as it was the first one approved, but there are several others available today. The benefits highlighted by the 2023 research go beyond simply extending the life of the kidney. According to the recent data, these medications also lower the risk of major adverse cardiac events and reduce the likelihood of urinary tract infections.
I actually started this medication a couple of months ago. Based on my recent urine dipstick tests, it seems to be doing great things for my kidney. I will be getting a blood test soon and will report back on those results, but my personal experience mirrors the positive outcomes we are seeing in the broader medical community.
Talk to Your Care Team
Interestingly, my transplant center did not initially bring this option up to me. It was my nephrologist who suggested it after I asked about early research. She advised me that as long as my transplant team approved, it was a viable option.
Because this is a relatively new application of the drug, you might not be automatically offered this treatment. You must be proactive. Bring up the SGLT2 inhibitor kidney transplant conversation with your transplant center, your nephrologist, or whoever manages your care. It could mean a longer-lasting kidney and better cardiovascular health.
Conclusion
As a natural health professional, I usually focus on nutrition, diet, and supplements to support the body. However, I always touch on medications when I feel they are genuinely important. The new SGLT2 inhibitor kidney transplant research is exactly that—a crucial development that every recipient should know about.
Thanks for reading and watching! If you are new here, make sure to check out our other resources and videos. We have a whole section dedicated to kidney transplants and how to help them last as long as possible.
